When thresholds were set at PSA > 10 ng/mL, 58.33% of significant PCa patients in the external validation cohort were missed, respectively; Surprisingly, the established technique was able to detect 93.33% of clinically significant prostate cancer. The gene discussed is KLK3; the disease is posterior cortical atrophy.